In the past week, SWTX stock has gone up by 7.98%, with a monthly gain of 1.19% and a quarterly surge of 6.14%. The volatility ratio for the week is 6.01%, and the volatility levels for the last 30 days are 5.41% for SpringWorks Therapeutics Inc The simple moving average for the last 20 days is 6.49% for SWTX stock, with a simple moving average of 35.45% for the last 200 days.
Is It Worth Investing in SpringWorks Therapeutics Inc (NASDAQ: SWTX) Right Now?
Moreover, the 36-month beta value for SWTX is 0.84. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SWTX is 62.80M and currently, short sellers hold a 16.79% of that float. On May 02, 2024, SWTX’s average trading volume was 1.15M shares.
SWTX) stock’s latest price update
SpringWorks Therapeutics Inc (NASDAQ: SWTX) has seen a rise in its stock price by 0.32 in relation to its previous close of 46.69. However, the company has experienced a 7.98% gain in its stock price over the last five trading sessions. InvestorPlace reported 2024-03-13 that While the technology sector has been enjoying ridiculous returns, it’s inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn’t received the same fervor.
Analysts’ Opinion of SWTX
Many brokerage firms have already submitted their reports for SWTX stocks, with Guggenheim repeating the rating for SWTX by listing it as a “Buy.” The predicted price for SWTX in the upcoming period, according to Guggenheim is $75 based on the research report published on February 05, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see SWTX reach a price target of $45. The rating they have provided for SWTX stocks is “Buy” according to the report published on December 01st, 2022.
H.C. Wainwright gave a rating of “Buy” to SWTX, setting the target price at $101 in the report published on January 19th of the previous year.
SWTX Trading at -1.27% from the 50-Day Moving Average
After a stumble in the market that brought SWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.13% of loss for the given period.
Volatility was left at 5.41%, however, over the last 30 days, the volatility rate increased by 6.01%, as shares surge +1.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.06% lower at present.
During the last 5 trading sessions, SWTX rose by +7.98%, which changed the moving average for the period of 200-days by +56.92% in comparison to the 20-day moving average, which settled at $44.01. In addition, SpringWorks Therapeutics Inc saw 28.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SWTX starting from Pichl Daniel, who sale 15,000 shares at the price of $50.10 back on Feb 16 ’24. After this action, Pichl Daniel now owns 45,212 shares of SpringWorks Therapeutics Inc, valued at $751,550 using the latest closing price.
Ashar Bhavesh, the Chief Commercial Officer of SpringWorks Therapeutics Inc, sale 4,834 shares at $49.32 during a trade that took place back on Feb 05 ’24, which means that Ashar Bhavesh is holding 58,154 shares at $238,435 based on the most recent closing price.
Stock Fundamentals for SWTX
Current profitability levels for the company are sitting at:
- -15.3 for the present operating margin
- 0.85 for the gross margin
The net margin for SpringWorks Therapeutics Inc stands at -14.31. The total capital return value is set at -0.53. Equity return is now at value -54.90, with -47.95 for asset returns.
Based on SpringWorks Therapeutics Inc (SWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -31.57. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 80.16.
Currently, EBITDA for the company is -341.35 million with net debt to EBITDA at 0.49. When we switch over and look at the enterprise to sales, we see a ratio of 146.63. The receivables turnover for the company is 3.78for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.41.
Conclusion
To wrap up, the performance of SpringWorks Therapeutics Inc (SWTX) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
